USING OF IMMUNOHISTOCHEMICAL MARKER HBME-1 IN OPTIMIZING THE DIAGNOSIS OF FOLLICULAR THYROID CARCINOMAS

AUTHORS:
O. Tovkai (Kyiv, Ukraine) , O. Nechai (Kyiv, Ukraine) , N. Belemets (Kyiv, Ukraine) , O. Huz (Kyiv, Ukraine) , D. Kvitka (Kyiv, Ukraine)
Background:
To optimize the differential diagnosis between follicular adenoma (FA) and follicular thyroid carcinoma (FTC) using the immunohistochemical (IHC) marker HBME-1 on the histological material of patients who were operated on for nodular goiter with cytology corresponding to the Bethesda classification III, IV, V.
Methods:
124 patients who were operated on for follicular nodular neoplasms with a cytological conclusion according to Bethesda "Gray zone" and had a histological conclusion (НС): FTC - 23 (18.5%); FA - 101 (81.5%). IHC was performed using mouse monoclonal antibodies against human HBME-1 ("Bio SB", USA). Evaluation criteria are made according to the strength of staining (from 0 to 3).
Results:
According to the strength of the intensity of IGH staining, an increase in the percentage of the diagnosis of FTC can be traced (p<0.05) respectively: 0 - 11.1%, 1 - 12.7%, 2 - 25%, 3 - 36.4%. HC findings were reexamined among FA that had the strongest staining reaction, in 3 (2.97%) cases the diagnosis was changed to FTC. Accordingly, the total number of established FTC increased to 26 (20.96%). These cases showed a good positive result regarding the use of HMBE-1 IHC study on FA preparations for the purpose of diagnostic search for FTC.
Conclusions:
HBME-1 can serve as an IGC marker for the differential diagnosis of FA and FTC, so among the cases diagnosed as FA, after the study, the diagnosis was changed to FTC in 2.97% of patients.